What do German Molecular Tumor Boards recommend in patients with PIK3CA mutated tumors? - Launch and first results from the German TEAM-D Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D)

Ina Pretzell; Alexander Desuki; Annalen Bleckmann; Sonja Loges; Anke Reinacher-Schick; C Benedikt Westphalen; Sebastian Lange; TEAM-D Participants

doi:10.1159/000539217

What do German Molecular Tumor Boards recommend in patients with PIK3CA mutated tumors? - Launch and first results from the German TEAM-D Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D)

Oncol Res Treat. 2024 May 7. doi: 10.1159/000539217. Online ahead of print.

Authors

Ina Pretzell, Alexander Desuki, Annalen Bleckmann, Sonja Loges, Anke Reinacher-Schick, C Benedikt Westphalen, Sebastian Lange; TEAM-D Participants

Collaborators

TEAM-D Participants:
Heiko Becker¹, Stephanie Berger², Sylvia Bochum², Jens Christmann³, Maike Collienne⁴, Jana Davina Debus⁵, Antje Duda⁶, Ira Ekmekciu⁷, Irene Esposito⁸, Georg Evers⁹, Anke Fleischhauer¹⁰, Marius Fried¹¹, Mathias Friedrich¹², Stefanie Gögel⁶, Lena Häberle¹³, Kathrin Heinrich¹⁴, Thorsten Götze¹⁵, Thomas Kindler¹⁶, Markus Knott¹⁷, Lionel Larribère², Elisabeth Mack¹⁸, Uwe Martens¹⁹, Nadina Ortiz-Brüchle²⁰, Daniel Pieh²¹, Michael Quante²², Marcel Romey²³, Matthias Scheffler²⁴, Max Schmidt²⁵, Susann Schulze²⁶, Henning Schulze-Bergkamen²⁷, Dilyana Vladimirova², Daniel-Christoph Wagner²⁸, Eva Wardelmann²⁹, Sergio Armando Zapata Bonilla³⁰

Affiliations

¹ Department of Hematology, Oncology and Stem Cell Transplantation, Center for Personalized Medicine (ZPM), Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
² Department of Hematology and Oncology, Cancer Center Heilbronn-Franken, SLK Clinics Heilbronn GmbH, Heilbronn, Germany.
³ Institute of Pathology, Ruhr University, Bochum, Germany.
⁴ 1.) DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim; 2.) Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), Heidelberg, Germany.
⁵ Institute of Pathology, Klinikum Dortmund gGmbH, Dortmund, Germany.
⁶ West German Cancer Center, University Hospital Muenster, Muenster, Germany.
⁷ Department of Hematology and Oncology, St. Josef Hospital, Ruhr University, Bochum, Germany.
⁸ Institute of Pathology, Heinrich-Heine University and University Hospital of Duesseldorf, Duesseldorf, Germany.
⁹ 1.) Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany; 2.) West German Cancer Center, University Hospital Muenster, Muenster, Germany.
¹⁰ West German Cancer Center, University Hospital Essen, Essen, Germany.
¹¹ 1.) Clinic and Polyclinic for Internal Medicine III, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 2.) University Cancer Center Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
¹² TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich.
¹³ Institute of Pathology, Heinrich-Heine University and University Hospital of Düsseldorf, Germany.
¹⁴ 1.) Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, München, Germany; 2.) German Cancer Consortium (DKTK); Partner Site Munich, Munich, Germany.
¹⁵ 1.) Northwest Hospital Frankfurt, University Cancer Center Frankfurt, Frankfurt am Main, Germany; 2.) Institute of Clinical Cancer Research IKF at Northwest Hospital, Frankfurt am Main, Germany.
¹⁶ 1.) University Cancer Center, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 2. 3rd Medical Department, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 3.) TRON-Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 4.) German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, a partnership between DKFZ and University Medical Center Mainz, Germany.
¹⁷ Stuttgart Cancer Center - Tumorzentrum Eva Mayr-Stihl, Klinikum Stuttgart, Stuttgart, Germany.
¹⁸ Department of Hematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany.
¹⁹ 1.) Department of Hematology and Oncology, Cancer Center Heilbronn-Franken, SLK Clinics Heilbronn GmbH, Heilbronn, Germany; 2.) MOLIT Institute for Personalized Medicine, Heilbronn, Germany.
²⁰ 1.) Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Aachen, Germany; 2.) Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.
²¹ Institute of Humangenetics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
²² Department of Internal Medicine II, University Hospital Freiburg, Freiburg, Germany.
²³ Institute of Pathology, Philipps-Universität Marburg and University Hospital Marburg, Marburg, Germany.
²⁴ Department I of Internal Medicine, Center for Integrated Oncology ABCD, University Hospital of Cologne.
²⁵ 1.) Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2.) Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 3.) German Cancer Consortium and German Cancer Research Center, Partner Site Berlin, Germany.
²⁶ Krukenberg Cancer Center Halle, University Hospital Halle, Halle (Saale), Germany.
²⁷ St. Mary Hospital Wesel, Department for Internal Medicine II, Wesel, Germany.
²⁸ Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
²⁹ Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany.
³⁰ University Cancer Center Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

PMID: 38714183
DOI: 10.1159/000539217

Abstract

Background and rationale: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.

Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.

Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.

Conclusions: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.

S. Karger AG, Basel.